NASDAQ:MLYS | Free Cash Flow | Mineralys Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2022-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$39.47M
2025-12-31-$37.89M
2025-03-31-$45.49M
2024-12-31-$66.84M
2024-03-31-$19.14M
2023-12-31-$28.98M
2023-03-31-$12.78M
2022-12-31-$10.19M
2022-03-31-$6.58M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$142.42M
2024-12-31-$166.31M
2023-12-31-$81.17M
2022-12-31-$29.22M